CRISPR-based screens uncover determinants of immunotherapy response in multiple myeloma

Acquired Resistance to Antibody-Drug Conjugates

(2019) Denis Collins et al.   Cancers

Chimeric antigen receptor T cell immunotherapy for multiple myeloma: A review of current data and potential clinical applications

(2019) Sandra P. Susanibar Adaniya et al.   AMERICAN JOURNAL OF HEMATOLOGY

B cell maturation antigen–specific CAR T cells are clinically active in multiple myeloma

(2019) Adam D. Cohen et al.   JOURNAL OF CLINICAL INVESTIGATION

Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma

(2019) Noopur Raje et al.   NEW ENGLAND JOURNAL OF MEDICINE

γ-secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma

(2019) Margot J. Pont et al.   BLOOD

Systematic Immunotherapy Target Discovery Using Genome-Scale In Vivo CRISPR Screens in CD8 T Cells

(2019) Matthew B. Dong et al.   CELL

CRISPR-Cas9 screens identify regulators of antibody–drug conjugate toxicity

(2019) C. Kimberly Tsui et al.   Nature Chemical Biology

CRISPR Interference-Based Platform for Multimodal Genetic Screens in Human iPSC-Derived Neurons

(2019) Ruilin Tian et al.   NEURON

Integrated drug profiling and CRISPR screening identify essential pathways for CAR T-cell cytotoxicity

(2019) Olli Dufva et al.   BLOOD

Inhibition of class IIa histone deacetylase activity by gallic acid, sulforaphane, TMP269, and panobinostat

(2018) Sin Young Choi et al.   BIOMEDICINE & PHARMACOTHERAPY

T Cells Genetically Modified to Express an Anti–B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma

(2018) Jennifer N. Brudno et al.   JOURNAL OF CLINICAL ONCOLOGY

HDP-101: Preclinical evaluation of a novel anti-BCMA antibody drug conjugates in multiple myeloma.

(2018) Andreas Pahl et al.   JOURNAL OF CLINICAL ONCOLOGY

Proteomics reveals signal peptide features determining the client specificity in human TRAP-dependent ER protein import

(2018) Duy Nguyen et al.   Nature Communications

Tumor Antigen Escape from CAR T-cell Therapy

(2018) Robbie G. Majzner et al.   Cancer Discovery

Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy

(2018) Shih-Feng Cho et al.   Frontiers in Immunology

Comparative Flavivirus-Host Protein Interaction Mapping Reveals Mechanisms of Dengue and Zika Virus Pathogenesis

(2018) Priya S. Shah et al.   CELL

Acquired mechanisms of immune escape in cancer following immunotherapy

(2018) J. Bryan Iorgulescu et al.   Genome Medicine

Combined CRISPRi/a-Based Chemical Genetic Screens Reveal that Rigosertib Is a Microtubule-Destabilizing Agent

(2017) Marco Jost et al.   MOLECULAR CELL

CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity

(2017) Marian L. Burr et al.   NATURE

CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma

(2016) Inger S. Nijhof et al.   BLOOD

Compact and highly active next-generation libraries for CRISPR-mediated gene repression and activation

(2016) Max A Horlbeck et al.   eLife

γ-secretase directly sheds the survival receptor BCMA from plasma cells

(2015) Sarah A. Laurent et al.   Nature Communications

Genome-Scale CRISPR-Mediated Control of Gene Repression and Activation

(2014) Luke A. Gilbert et al.   CELL

Functional genomics platform for pooled screening and generation of mammalian genetic interaction maps

(2014) Martin Kampmann et al.   Nature Protocols

An allosteric Sec61 inhibitor traps nascent transmembrane helices at the lateral gate

(2014) Andrew L MacKinnon et al.   eLife

Selective class IIa histone deacetylase inhibition via a nonchelating zinc-binding group

(2013) Mercedes Lobera et al.   Nature Chemical Biology

Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma

(2012) L. Santo et al.   BLOOD

Preclinical Profile of a Potent  -Secretase Inhibitor Targeting Notch Signaling with In vivo Efficacy and Pharmacodynamic Properties

(2009) L. Luistro et al.   CANCER RESEARCH

The novel histone deacetylase inhibitor, LBH589, induces expression of DNA damage response genes and apoptosis in Ph- acute lymphoblastic leukemia cells

(2008) A. Scuto et al.   BLOOD